S. Kobayashi

S. Kobayashi, D. Costa, J. A. Zerillo, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Structural, biochemical, and clinical characterization of Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations in lung cancer (Science Translational Medicine (2014) 6, (225er1))

M. Meyerson, M. Hanna, L. Sequist, 2014 .

Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.

D. Tenen, S. Kobayashi, D. Costa, 2010, Blood.

NAD Modulates DNA Methylation and Cell Differentiation

Mahmoud A. Bassal, S. Kobayashi, B. Ghinassi, 2021, Cells.

NAD Modulates DNA Methylation and Cell Differentiation

Mahmoud A. Bassal, S. Kobayashi, Susumu S. Kobayashi, 2020, bioRxiv.

Prognostic significance of β-catenin expression in patients with non-small cell lung cancer: a meta-analysis.

S. Kobayashi, K. Phan, M. Katoh, 2017, Translational lung cancer research.

Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing.

M. Meyerson, D. Tenen, W. Richards, 2012, Lung cancer.

Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.

S. Kobayashi, D. Costa, Susumu S. Kobayashi, 2020, The oncologist.

Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations.

S. Kobayashi, D. Costa, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Coactivator-associated arginine methyltransferase I [CARM1; also known as protein arginine methyltransferase 4 (PRMT4)] is one of nine members of the protein arginine methyltransferase (PRMT)

M. Bhasin, D. Tenen, S. Kobayashi, 2010 .

Acquired Resistance to the ALK Inhibitor Crizotinib in the Absence of an ALK Mutation

S. Kobayashi, D. Costa, Susumu S. Kobayashi, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

S. Kobayashi, D. Costa, Kim-Son H Nguyen, 2009, Clinical lung cancer.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

S. Digumarthy, A. Iafrate, L. Chirieac, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non-Small-Cell Lung Cancer

S. Kobayashi, D. Costa, A. Ackerman, 2012 .

EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.

S. Kobayashi, D. Costa, A. Ackerman, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PHOSPHORYLATION OF C/EBP α REGULATES GLUT4 EXPRESSION AND GLUCOSE TRANSPORT IN ADIPOCYTES

D. Tenen, S. Kobayashi, O. MacDougald, 2008 .

Phosphorylation of CCAAT/Enhancer-binding Protein α Regulates GLUT4 Expression and Glucose Transport in Adipocytes*

D. Tenen, S. Kobayashi, O. MacDougald, 2008, Journal of Biological Chemistry.

Suppression of multiple anti‐apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms

S. Kobayashi, R. Welner, Susumu S. Kobayashi, 2021, Cancer science.

CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha.

M. Sporn, D. Tenen, M. Konopleva, 2007, Blood.

Alternative splicing of APOBEC3D generates functional diversity and its role as a DNA mutator

R. Yamashita, S. Kobayashi, M. Fujii, 2016, International Journal of Hematology.

Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation.

D. Tenen, S. Kobayashi, A. Kamal, 2019, Bioorganic & medicinal chemistry letters.

Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBPα

D. Tenen, S. Kobayashi, R. Sridhar, 2018, Molecules.

NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells

S. Kobayashi, F. Traina, Susumu S. Kobayashi, 2022, Scientific Reports.

Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms

S. Kobayashi, Susumu S. Kobayashi, T. Mantello Bianco, 2022, Frontiers in Immunology.

Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer.

S. Kobayashi, D. Costa, D. Rangachari, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dual speciﬁcity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells

A. Borczuk, T. LaFramboise, S. Kobayashi, 2010 .

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

S. Kobayashi, D. Costa, Weiwei Tan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erlotinib-associated alopecia in a lung cancer patient.

S. Kobayashi, D. Costa, S. Schumer, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer

T. Betsuyaku, T. Kohno, H. Asamura, 2021, Cancer Research.

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

M. Meyerson, D. Tenen, H. Ji, 2005, Cancer research.

Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen‐activated protein Kinase (MAPK) and Phosphatidylinositol‐3‐kinase (PI3K)/AKT pathways

Lewis C Cantley, L. Cantley, S. Kobayashi, 2012, Journal of cellular physiology.

β-catenin contributes to lung tumor development induced by EGFR mutations.

Kwok-Kin Wong, Yuichiro Hayashi, Kenzo Soejima, 2014, Cancer research.

Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.

S. Kobayashi, D. Costa, S. Kobayashi, 2014, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

CARM1 is required for proper control of proliferation and differentiation of pulmonary epithelial cells

M. Bhasin, D. Tenen, S. Kobayashi, 2010, Development.

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

S. Kobayashi, D. Costa, Susumu Kobayashi, 2012, The Lancet. Oncology.

EGFR-mutated lung cancer: a paradigm of molecular oncology

Balazs Halmos, S. Kobayashi, T. Boggon, 2010, Oncotarget.

Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells.

A. Borczuk, T. LaFramboise, S. Kobayashi, 2010, Carcinogenesis.

Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells.

D. Rimm, S. Kobayashi, K. Politi, 2016, Cell reports.

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

P. Jänne, D. Tenen, J. Engelman, 2009, Clinical Cancer Research.

Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells

T. Mukohara, S. Kobayashi, M. Fujii, 2020, Scientific Reports.

EGFR-Directed Therapy in Lung Cancer

S. Kobayashi, B. Halmos, D. Costa, 2023 .

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

D. Tenen, S. Kobayashi, T. Boggon, 2007, PLoS medicine.

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

S. Kobayashi, D. Costa, Susumu S. Kobayashi, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.

J. Minna, S. Kobayashi, C. Moran, 2023, Cancer cell.

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

S. Kobayashi, S. Matsumoto, K. Yoh, 2021, Nature.

Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations

Shingo Matsumoto, Fumie Ono, Koichi Goto, 2019, Proceedings of the National Academy of Sciences.

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.

S. Kobayashi, D. Costa, H. Reddi, 2017, Lung cancer.

De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.

D. Dias-Santagata, A. Majid, S. Kobayashi, 2016, Lung cancer.

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

S. Kobayashi, D. Costa, S. Schulman, 2015, Lung cancer.

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer

T. Betsuyaku, S. Kobayashi, D. Costa, 2015, Oncotarget.

Identification and Characterization of ALK Kinase Splicing Isoforms in Non–Small-Cell Lung Cancer

P. Jänne, S. Kobayashi, D. Costa, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells.

S. Kobayashi, I. Nakase, T. Takatani-Nakase, 2019, International journal of pharmaceutics.

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3–PD‐L1 ≥50% Expression in Lung Adenocarcinoma

S. Kobayashi, D. Costa, X. Le, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

D. Tenen, S. Kobayashi, D. Costa, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.

D. Tenen, S. Kobayashi, D. Costa, 2007, Lung cancer.

CCAAT/Enhancer Binding Protein β Is Dispensable for Development of Lung Adenocarcinoma

Kwok-Kin Wong, S. Kobayashi, D. Costa, 2015, PloS one.

CARM1 is required for proper control of proliferation and differentiation of pulmonary epithelial cells

M. Bhasin, D. Tenen, S. Kobayashi, 2010, Development.

Cancer Growth Factor Receptor ( EGFR ) Exon 20 Insertion Mutations in Lung Structural , Biochemical , and Clinical Characterization of Epidermal

M. Meyerson, M. Hanna, L. Sequist, 2013 .

Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center.

G. Michaud, J. Aronovitz, A. Majid, 2012, Journal of oncology practice.

Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations

M. Kris, D. Tenen, W. Pao, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

P. Jänne, D. Tenen, W. Pao, 2008, Clinical Cancer Research.

Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.

M. Meyerson, A. Lowell, D. Tenen, 2008, Cancer research.

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

P. Jänne, R. Weissleder, D. Tenen, 2006, Cancer cell.

Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations

P. Jänne, N. Hanna, D. Tenen, 2005 .

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.

P. Jänne, N. Hanna, D. Tenen, 2005, Journal of the National Cancer Institute.

Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

S. Kobayashi, A. Suzuki, K. Goto, 2021, Cancer Research.

The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example

T. Mitsudomi, S. Kobayashi, Susumu S. Kobayashi, 2011, The Annals of pharmacotherapy.

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.

S. Kobayashi, V. Miller, D. Costa, 2015, Clinical lung cancer.

Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.

T. Golub, M. Meyerson, S. Monti, 2006, Cancer research.

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs

T. Kohno, Y. Ohe, S. Kobayashi, 2021, Thoracic cancer.

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

L. Sequist, S. Kobayashi, D. Costa, 2018, Clinical Cancer Research.

Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.

D. Tenen, S. Kobayashi, T. Boggon, 2007, Cancer research.

TAS2940, a novel brain‐penetrable pan‐ERBB inhibitor, for tumors with HER2 and EGFR aberrations

S. Kobayashi, S. Mizuarai, S. Tsuji, 2022, Cancer science.

Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer

S. Kobayashi, D. Costa, Susumu S. Kobayashi, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Serum concentrations of Erlotinib at a dose of 25 mg daily.

S. Kobayashi, D. Costa, Susumu S. Kobayashi, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1

S. Kobayashi, K. Politi, Wei Zhang, 2023, British Journal of Cancer.

A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia.

R. Verhaak, C. Steidl, F. Rosenbauer, 2007, The Journal of clinical investigation.

Myeloid lncRNA LOUP Mediates Opposing Regulatory Effects of RUNX1 and RUNX1-ETO in t(8;21) AML.

Mahmoud A. Bassal, P. Pandolfi, D. Tenen, 2021, Blood.

TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations

S. Kobayashi, D. Costa, K. Goto, 2019, Molecular Cancer Research.

ZNF143 protein is an important regulator of the myeloid transcription factor C/EBPα

Pu Zhang, Meritxell Alberich-Jorda, Daniel G. Tenen, 2017, The Journal of Biological Chemistry.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.

S. Kobayashi, D. Costa, X. Le, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeting transcription factors in acute myeloid leukemia

S. Kobayashi, Susumu S. Kobayashi, H. Takei, 2018, International Journal of Hematology.

Brief Report: EGFR-mutated lung cancers resistant to osimertinib through EGFR-C797S respond to 1st generation reversible EGFR inhibitors but eventually acquire EGFR-T790M/C797S in preclinical models and clinical samples.

C. Paweletz, P. Jänne, S. Kobayashi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer

S. Kobayashi, D. Costa, Susumu S. Kobayashi, 2020, JTO Clinical and Research Reports.

Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with EGFR Mutations at a High Cell Density.

A. Sugiyama, S. Kobayashi, I. Nakase, 2017, Anticancer research.

Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy.

J. Kutok, F. Rosenbauer, K. Wagner, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.

S. Kobayashi, D. Costa, Susumu Kobayashi, 2014, Lung cancer.

Decreased Activity of NK Cells in Myeloproliferative Neoplasms

D. Tenen, S. Kobayashi, E. Rego, 2015 .

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

M. Kris, W. Pao, J. Warner, 2010 .